Reference
Yagi K, et al. The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases. BMC Infectious Diseases 17: 558, No. 1, 09 Aug 2017. Available from: URL: http://doi.org/10.1186/s12879-017-2665-5 - Japan
Rights and permissions
About this article
Cite this article
Amikacin sulfate. Reactions Weekly 1671, 26 (2017). https://doi.org/10.1007/s40278-017-36460-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-017-36460-6